» Authors » Karin Williamson

Karin Williamson

Explore the profile of Karin Williamson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 1291
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, et al.
Int J Gynecol Cancer . 2025 Jan; 35(1):100001. PMID: 39878257
Objective: The Laparoscopic Approach to Cervical Cancer trial demonstrated that minimally invasive radical hysterectomy was associated with worse disease-free survival and overall survival among women with early-stage cervical cancer. It...
2.
Kwon J, McTaggart-Cowan H, Ferguson S, Samouelian V, Lambaudie E, Guyon F, et al.
J Gynecol Oncol . 2024 Oct; 35(6):e117. PMID: 39453395
Objective: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for...
3.
Ferguson S, Brotto L, Kwon J, Samouelian V, Ferron G, Maulard A, et al.
J Clin Oncol . 2024 Oct; 43(2):167-179. PMID: 39353164
Purpose: Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in low-risk...
4.
Plante M, Kwon J, Ferguson S, Samouelian V, Ferron G, Maulard A, et al.
N Engl J Med . 2024 Feb; 390(9):819-829. PMID: 38416430
Background: Retrospective data suggest that the incidence of parametrial infiltration is low in patients with early-stage low-risk cervical cancer, which raises questions regarding the need for radical hysterectomy in these...
5.
Dilley J, Gentry-Maharaj A, Ryan A, Burnell M, Manchanda R, Kalsi J, et al.
Gynecol Oncol . 2023 Nov; 179:123-130. PMID: 37980767
Objective: UKCTOCS provides an opportunity to explore symptoms in preclinical invasive epithelial ovarian cancer (iEOC). We report on symptoms in women with pre-clinical (screen-detected) cancers (PC) compared to clinically diagnosed...
6.
Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R, et al.
Lancet Oncol . 2023 Sep; 24(9):1018-1028. PMID: 37657461
Background: In UKCTOCS, there was a decrease in the diagnosis of advanced stage tubo-ovarian cancer but no reduction in deaths in the multimodal screening group compared with the no screening...
7.
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al.
Lancet . 2021 May; 397(10290):2182-2193. PMID: 33991479
Background: Ovarian cancer continues to have a poor prognosis with the majority of women diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)...
8.
Kalsi J, Gentry-Maharaj A, Ryan A, Singh N, Burnell M, Massingham S, et al.
Cancers (Basel) . 2021 Mar; 13(4). PMID: 33670571
Randomised controlled trials of ovarian cancer (OC) screening have not yet demonstrated an impact on disease mortality. Meanwhile, the screening data from clinical trials represents a rich resource to understand...
9.
Menon U, McGuire A, Raikou M, Ryan A, Davies S, Burnell M, et al.
Br J Cancer . 2017 Jul; 117(5):619-627. PMID: 28742794
Background: To assess the within-trial cost-effectiveness of an NHS ovarian cancer screening (OCS) programme using data from UKCTOCS and extrapolate results based on average life expectancy. Methods: Within-trial economic evaluation...
10.
Jacobs I, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi J, et al.
Lancet . 2015 Dec; 387(10022):945-956. PMID: 26707054
Background: Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian...